Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Innovent will supply sintilimab for the collaborated clinical trial
Furthering cell therapy ambition across oncology and autoimmune diseases
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Subscribe To Our Newsletter & Stay Updated
